Stock Report: C.R. Bard Inc. (BCR) Report Updated: May 20, 2013 | Print This Page

C. R. Bard, Inc. and its subsidiaries design, manufacture, package, distribute, and sell medical, surgical, diagnostic, and patient care devices worldwide. The company’s vascular products include percutaneous transluminal angioplasty catheters, chronic total occlusions catheters, guidewires, introducers, and accessories; peripheral vascular stents and stent grafts, vena cava filters, and biopsy devices; electrophysiology products comprising electrophysiology laboratory systems and diagnostic, therapeutic, and temporary pacing electrode catheters; and fabrics, meshes, and implantable vascular grafts. Its urology products consists of infection control Foley catheters to reduce the rate of urinary tract infections; surgical slings to treat stress urinary incontinence; fecal incontinence products; natural and synthetic devices to treat pelvic floor and vaginal prolapse; brachytherapy services, devices, and radioactive seeds to treat prostate cancer; intermittent urinary drainage catheters, and urine monitoring and collection systems; ureteral stents; specialty devices for ureteroscopic procedures and stone removal; and catheter stabilization devices. The company’s oncology products comprise specialty vascular access catheters and ports, vascular access ultrasound devices, dialysis access catheters, and enteral feeding devices to treat and manage various cancers, and other diseases and disorders. Its surgical specialty products include soft tissue repair products, such as hernia repair implants consisting of synthetic and natural-tissue configurations, and hernia implant fixation devices; irrigation devices for orthopedic, laparoscopic, and gynecological procedures; and products for topical hemostasis. The company markets its products to hospitals, individual healthcare professionals, extended care facilities, and alternate site facilities. C. R. Bard, Inc. was founded in 1907 and is headquartered in Murray Hill, New Jersey.